Genetic Markers Predict Semaglutide Response in American Males: GWAS Insights
Reading Time: 2 minutes Introduction Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a cornerstone in the management of type 2 diabetes and obesity. Its efficacy in promoting weight loss and glycemic control is well-documented; however, individual responses to the drug can vary significantly. This variability prompts an exploration into the genetic underpinnings that may influence how American males respond to semaglutide. A recent genome-wide association study (GWAS) sheds light on this critical aspect, offering insights that could personalize and optimize therapeutic strategies. The Study and Its Methodology The GWAS in question focused on a cohort of American males, examining the genetic...


